GLP-1 weight loss drugs linked to heightened GI risks, says new study

FHS
October 5, 2023
11:04 pm

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

Cybin Completes Phase 2 Dosing Study For Major Depressive Disorder

Cybin Inc. positive news cycle keeps churning out positive developments. Today, the company announced the successful completion of dosing for the final cohort within the

October 3, 2023

These 12 Chinese companies are poised to transform CRISPR gene-editing

As the race between U.S. and Chinese biotech companies heats up, the competition is particularly fierce in one field: CRISPR gene editing. China has rapidly

March 17, 2025

Gene therapy repairs neural connections in mice with Hurler syndrome

A new study from the University of Minnesota is the first to demonstrate the ability for gene therapy to repair neural connections for those with

August 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.